The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: What is the clinical significance?

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 13, 2008, Pages 2295-2303

  Rizzo, Manfredi ^a   Christ, Emanuel R ^b   Rini, Giovam Battista ^a   Spinas, Giatgen A ^c   Berneis, Kaspar ^c  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cardiovascular risk; Dense low density lipoprotein; Diabetes; Low density lipoprotein size; Pioglitazone; Rosiglitazone; Small

Indexed keywords

APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; CARDIOVASCULAR AGENT; FENOFIBRATE; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 52249118511     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.13.2295     Document Type: Review

References (80)

1. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med 2007;356:2522-4
2. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004;27:1496-504
3. Taskinen MR. Diabetic dyslipidaemia. From basic research to clinical practice. Diabetologia 2003;46:733-49
4. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495-506
5. Griffin BA, Caslake MJ, Yip B, et al. Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 1990;83:59-67
6. Rizzo M, Berneis K. Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention? J Atheroscler Thromb 2005;12:237-9
7. Wierzbicki AS. Quality as well as quantity? Beyond low-density lipoprotein-cholesterol - the role of particle size. Int J Clin Pract 2007;61:1780-2
8. Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 1997;17:3542-56
9. National cholesterol education program. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
10. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 2000;23:1605-11
11. Gomez-Perez FJ, Fanghanel-Salmon G, Barbosa JA, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002;18:127-34
12. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54
13. Chiquerte E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-104
14. Deeg MA, Buse JB, Goldberg RB, et al. On behalf of the glai study investigators. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007;30:2458-2464
15. Berneis K, Rizzo M, Stettler C, et al. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with typc-2 diabetes. Expert Opin Pharmacother 2008;9:343-9
16. Austin MA, Mykkanen L, Kuusisto J, et al. Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation 1995;92:1770-8
17. Reaven GM, Chen YD, Jeppesen J, et al. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 1993;92:141-6
18. Selby JV, Austin MA, Newman B, et al. LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation 1993;88:381-7
19. Feingold KR, Grunfeld C, Pang M, et al. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 1992;12:1496-502
20. Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003;52:453-62
21. Berneis K, Jeanneret C, Muser J, et al. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes. Metabolism 2005;54:227-34
22. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997;146:483-94
23. Craven TE, Ryu JE, Espeland MA, et al. Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis. A case-control study. Circulation 1990;82:1230-42
24. Wofford JL, Kahl FR, Howard GR, et al. Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. Arterioscler Thromb 1991;11:1786-94
25. Winkler K, Abletshauser C, Hoffmann MM, et al. Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action. J Clin Endocrinol Metab 2002;87(12):5485-90
26. Kazama H, Usui S, Okazaki M, et al. Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes. Diabetes Res Clin Pract 2003;59(3):181-9
27. Geiss HC, Schwandt P, Parhofer KG. Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and in patients with diabetes mellitus and mixed hyperlipoproteinemia. Exp Clin Endocrinol Diabetes 2002;110(4):182-7
28. Pontrelli L, Parris W, Adeli K, Cheung RC. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism 2002;51(3):334-42
29. Wagner AM, Jorba O, Bonet R, et al. Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 2003;88(7):3212-7
30. Ikejiri A, Hirano T, Murayama S, et al. Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients. Metabolism 2004;53(9):1113-7
31. Freed MI, Ratner R, Marcovina SM, et al. Rosiglitazone study 108 investigators: effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellicus. Am J Cardiol 2002;90(9):947-52
32. Frost RJ, Otto C, Geiss HC, et al. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol 2001;87(1):44-8
33. Geiss HC, Otto C, Schwandt P, Parhofer KG. Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects. Metabolism 2001;50(8):983-8
34. Soedamah-Muthu SS, Colhoun HM, Thomason MJ, et al. Cards investigators. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis 2003;167:243-55
35. Lahdenpera S, Tilly-Kiesi M, Vuorinen-Markkola H, et al. Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes. Diabetes Care 1993;16:584-92
36. Feher MD, Castake M, Foxton J, et al. Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate. Diabetes Metab Res Rev 1999;15:395-9
37. Tan CE, Chew LS, Tai ES, et al. Benefits of micronised fenofibrate in type 2 diabetes mellitus subjects with good glycemic control. Atherosclerosis 2001;154:469-74
38. Vakkilainen J, Steiner G, Ansquer JC, et al.; DAIS Group. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003;107:1733-7
39. Keech A, Simes RJ, Barter P, et al. Field Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61
40. Patti L, Maffettone A, Iovine C, et al. Long-term effects of fish oil on lipoprotein subfiractions and low density lipoprotein size in non-insulin-dependent diabetic patients with hypertriglyceridemia. Atherosclerosis 1999;146:361-7
41. Petersen M, Pedersen H, Major-Pedersen A, et al. Effect of fish oil versus corn oil supplementation on LDL and HDL subclasses in type 2 diabetic patients. Diabetes Care 2002;25:1704-8
42. Mostad IL, Bjerve KS, Lydersen S, Grill V. Effects of marine n-3 fatty acid supplementation on lipoprotein subclasses measured by nuclear magnetic resonance in subjects with type II diabetes. Eur J Clin Nutr 2008;62:419-29
43. Woodman RJ, Mori TA, Burke V, et al. Docosahexaenoic acid but not eicosapentaenoic acid increases LDL particle size in treated hypertensive type 2 diabetic patients. Diabetes Care 2003;26:253
44. Superko HR, Mcgovern ME, Raul E, Garrett B. Differential effect of two nicotinic acid preparations on low density lipoprotein subclass distribution in patients classified as low density lipoprotein pattern A, B, or 1. Am J Cardiol 2004;94:588-94
45. Pan J, Van JT Chan E, et al. Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes. Metabolism 2002;51:1120-7
46. Winkler K, Friedrich I, Baumstark MW, et al. Pioglitazone reduces atherogenic dense low density lipoprotein (LDL) particles in patients with type 2 diabetes mellitus. Br J Diabetes Vasc Dis 2002;2:1431-48
47. Perez A, Khan M, Johnson T, Karunaratne M. Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. Diabetes Vasc Dis Res 2004;1:44-50
48. Parhofer KG, Otto C, Geiss HC, et al. Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2 - results of a pilot study. Exp Clin Endocrinol Diabetes 2005;113:49-52
49. Lautamaki R, Nuutila P, Airaksinen KE, et al. The effect of PPARgamma-agonism on LDL subclass profile in patients with type 2 diabetes and coronary artery disease. Rev Diabet Stud 2006;3:31-8
50. Yu D, Murdoch SJ, Parikh SJ, et al. Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy. Diabetes Vasc Dis Res 2006;3:189-96
51. Rizzo M, Rini GB, Berneis K. The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes. Exp Clin Endocrinol Diabetes 2007;115:477-82
52. Cohn JS. Postprandial lipemia and remnant lipoproteins. Clin Lab Med 2006;26:773-86
53. Okumura K, Matsui H, Kawakami K, et al. Modulation of LDL particle size after an oral glucose load is associated with insulin levels. Clin Chim Acta 1998;276:143-55
54. Chappuis B, Braun M, Stettler C, et al. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab Res Rev 2007;23:392-9
55. Khan M, Berhanu P, Perez A. Effects of pioglitazone in combination with stable statin therapy on lipid levels in subjects with type 2 diabetes and dyslipidemia after treatment conversion from rosiglitazone: results from an open label study. Diabetes 2005;A137
56. Berhanu P, Kipnes MS, Khan MA, et al. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diabetes Vasc Dis Res 2006;3:39-44
57. Derosa G, D'angelo A, Ragonesi PD, et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006;31:375-83
58. Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 2001;12:297-230
59. Nagashima K, Lopez C, Donovan D, et al. Effects of the PPAR agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 2005;115:1323-32
60. Zhang L, Chawla A. Role of PPAR gamma in macrophage biology and atherosclerosis. Trends Endocrinol Metab 2004;15:500-5
61. Koshiyama H, Shimono D, Kuwamura N, et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001;86:3452-6
62. Nakamura T, Matsuda T, Kawagoe Y, et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 2004;53:1382-6
63. Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005;111:2525-31
64. Hedblad B, Zambanini A, Nilsson P, et al. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study. J Intern Med 2007;261:293-305
65. Stocker DJ, Taylor AJ, Langley RW, et al. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J 2007;153:445-e1-445.e6
66. Osman A, Otero J, Brizolara A, et al. Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Am Heart J 2004;147:e23
67. Takagi T, Yamamuro A, Tamita K, et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 2003;146:E5
68. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death for cardiovascular causes. N Engl J Med 2007;356:2457-71
69. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95
70. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8
71. Erdmann E, Dormandy JA, Charbonnel B, et al. Proactive investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007;49:1772-80
72. Rizzo M, Berneis K. Who needs to care about small, dense low density lipoproteins? Int J Clin Pract 2007;61:1949-56
73. Sacks FM, Campos H. Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab 2003;88:4525-32
74. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004;10:355-61
75. Ahmed W, Ziouzenkova O, Brown J, et al. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? J Intern Med 2007;262:184-98
76. Sakamoto J, Kimura H, Moriyama S, et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000;278:704-11
77. Narce M, Poisson JP. Novel PPARgamma-dependent and independent effects for thiazolidinediones. Curr Opin Lipidol 2003;14:651-2
78. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005;294:2581-6
79. Berton E. AstraZeneca drops diabetes drug Galida. Available from: http://www.reuters.co.uk [Last accessed 4 May 2006]
80. Brown JD, Plutzky J. Peroxisome proliferator activated receptors as transcriptional nodal points and therapeutic targets. Circulation 2007;115:518-33